Prostate Cancer

SAN FRANCISCO — The addition of pembrolizumab to docetaxel failed to significantly extend survival for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of the randomized phase 3 KEYNOTE-921 trial.

SAN FRANCISCO — Long-term androgen deprivation therapy as part of tri-modality therapy did not improve outcomes for men with localized high-risk prostate cancer, according to randomized phase 3 study results.

SAN FRANCISCO — Rucaparib significantly improved radiographic PFS compared with physician’s choice of therapy for men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to randomized phase 3 study results.

SAN FRANCISCO — The addition of talazoparib to first-line enzalutamide extended imaging-based PFS among men with metastatic castration-resistant prostate cancer, according to results of the randomized phase 3 TALAPRO-2 study.

SAN FRANCISCO — An artificial intelligence-derived biomarker enabled improved risk stratification for men with high-risk prostate cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.

Cancer mortality in the United States has declined by 33% since 1991, according to an American Cancer Society report released today.

A relationship between race and social determinants of health contributed to significantly higher prostate cancer-specific morality among Black men in the United States, results of a meta-analysis in JAMA Network Open showed.

Primary care providers frequently order prostate cancer screenings for older patients, even when they provide little value and could lead to false-positive results, a recent study found.

Black men have the highest rates of prostate cancer incidence and related mortality compared with all other racial and ethnic groups among U.S.-based men, results of an analysis published in European Urology showed.

Several novel treatment regimens for prostate cancer emerged during the past year.